Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism.
No previous study has investigated how the vaso-constrictive peptide Ang II impacts insulin action in isolated mammalian skeletal muscle. We investigated the molecular actions of Ang II on insulin signalling and glucose transport in skeletal muscle from lean Zucker rats. Soleus strips were incubated with insulin (5 mU/ml) and/or Ang II (500 nM) for 2 hours. Ang II caused significant (p < 0.05) inhibition of insulin-stimulated glucose transport (39%) and decreased phosphorylation of Akt Ser(473) (37%) and glycogen synthase kinase-3beta Ser(9) (42%) without affecting phosphorylation of IRS-1 Ser(307) or p38 MAPK. We used the superoxide dismutase mimetic, tempol (1 mM), to determine if reactive oxygen species (ROS) contribute to Ang II-mediated insulin resistance. Tempol partially reversed (42%) Ang II-induced inhibition of insulin-stimulated glucose transport. These results indicate that Ang II inhibits distal insulin signalling and insulin-stimulated glucose transport in isolated mammalian skeletal muscle, and that this effect is partially mediated by ROS.
Diamond-Stanic
Maggie K
MK
Muscle Metabolism Laboratory, Department of Physiology and Arizona Diabetes Program, University of Arizona College of Medicine, Tucson, AZ 85721-0093, USA.
Henriksen
Erik J
EJ
D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001692:Biological Transport; D005260:Female; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism* / Q000494:pharmacology; D020930:MAP Kinase Kinase Kinases; D008322:Mammals / Q000378:metabolism; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D011924:Rats, Zucker; D017382:Reactive Oxygen Species / Q000378:metabolism* / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism / Q000494:pharmacology
D007004:Hypoglycemic Agents; D007328:Insulin; D011518:Proto-Oncogene Proteins; D017382:Reactive Oxygen Species; D000804:Angiotensin II; D051057:Proto-Oncogene Proteins c-akt; D048051:p38 Mitogen-Activated Protein Kinases; D020930:MAP Kinase Kinase Kinases; C069937:MAP3K8 protein, human; D005947:Glucose
N Engl J Med. 2006 Oct 12;355(15):1551-62
16980380
Am J Physiol. 1999 Nov;277(5):E920-6
10567021
Free Radic Biol Med. 2009 Sep 1;47(5):593-9
19500665
J Biol Chem. 2005 Feb 11;280(6):4422-8
15574412
Hypertension. 2002 Dec;40(6):872-9
12468572
Eur J Pharmacol. 2005 Sep 27;520(1-3):179-87
16139267
N Engl J Med. 2000 Mar 30;342(13):905-12
10738048
Metabolism. 2007 Jul;56(7):931-8
17570255
Am J Physiol. 1996 Jun;270(6 Pt 1):E919-29
8764174
Regul Pept. 2000 Jul 28;91(1-3):21-7
10967199
N Engl J Med. 2000 Jan 20;342(3):145-53
10639539
Hypertension. 1996 Apr;27(4):854-8
8613260
Hypertension. 2007 Aug;50(2):384-91
17533199
Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E353-9
15494608
Free Radic Biol Med. 2009 Nov 15;47(10):1486-93
19703555
Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1074-81
15657091
Lancet. 1999 Feb 20;353(9153):611-6
10030325
Hypertension. 2001 Oct;38(4):884-90
11641303
JAMA. 2002 Sep 25;288(12):1491-8
12243636
J Appl Physiol (1985). 1994 May;76(5):1862-7
8063642
Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E615-21
18089761
J Clin Invest. 1997 Nov 1;100(9):2158-69
9410892
Metabolism. 2005 Dec;54(12):1659-68
16311101
Metabolism. 1995 Feb;44(2):267-72
7869926
J Biol Chem. 2006 Nov 17;281(46):35137-46
16982630
Free Radic Biol Med. 2006 Sep 1;41(5):818-24
16895802